Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Net Income (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Net Income for 10 consecutive years, with -$122.6 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 128.58% to -$122.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$569.0 million through Dec 2025, down 8028.57% year-over-year, with the annual reading at -$569.0 million for FY2025, 8028.57% down from the prior year.
  • Net Income for Q4 2025 was -$122.6 million at Ultragenyx Pharmaceutical, up from -$180.4 million in the prior quarter.
  • The five-year high for Net Income was $485.4 million in Q4 2023, with the low at -$245.1 million in Q3 2022.
  • Average Net Income over 5 years is -$87.1 million, with a median of -$143.6 million recorded in 2021.
  • The sharpest move saw Net Income plummeted 583.62% in 2021, then surged 412.87% in 2023.
  • Over 5 years, Net Income stood at -$124.8 million in 2021, then decreased by 24.34% to -$155.2 million in 2022, then soared by 412.87% to $485.4 million in 2023, then fell by 11.67% to $428.8 million in 2024, then tumbled by 128.58% to -$122.6 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$122.6 million, -$180.4 million, and -$115.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.